Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
SAF312 - TRPV1 antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04630158 SAHARA (CSAF312B12201)
Chronic ocular surface pain
Phase 2
150
Change in mean pain severity Visual Analog Scale
Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye drops,
twice daily
Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops, twice daily
Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops, twice daily
Subjects with CICP persisting at least for 4 months after refractive surgery and
chronicity confirmed during the observational period.
Target Patients
Read-out Milesstone(s)
Publication
2022
TBD
125 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation